Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia.
Clin Chest Med
; 44(2): 299-319, 2023 06.
Article
in English
| MEDLINE | ID: covidwho-2271631
ABSTRACT
Morbidity and mortality from COVID-19 is due to severe inflammation and end-organ damage caused by a hyperinflammatory response. Multiple immunomodulatory agents to attenuate this response have been studied. Corticosteroids, specifically dexamethasone, have been shown to reduce mortality in hospitalized patients who require supplemental oxygen. Interleukin-6 antagonist, tocilizimab, and Janus kinase inhibitors have also been shown to reduce mortality. However, patients who have severe pulmonary end-organ damage requiring mechanical ventilation or extracorporeal membrane oxygenation appear not to benefit from immunomodulatory therapies. This highlights the importance of appropriate timing to initiate immunomodulatory therapies in the management of severe COVID-19 disease.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia
/
COVID-19
Limits:
Humans
Language:
English
Journal:
Clin Chest Med
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS